Obesity is a chronic complex disease characterized by excessive adiposity that increases risk for multiple noncommunicable diseases including type 2 diabetes, cardiovascular disease, and some cancers.
A study links sugary drink consumption to anxiety in adolescents, while separate research shows parental substance use patterns strongly influence teen consumption, with authoritative parenting styles offering protective effects.
Tent5a was identified as a positive regulator of insulin production in pancreatic beta cells. Overexpression extended poly(A) tails of insulin transcripts and increased insulin content.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
Rhythm reported Q1 2026 IMCIVREE revenue of $60.1 million and said more than 150 patient start forms were received after U.S. approval in acquired hypothalamic obesity. The company also cited European authorization and a Japanese application under review.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Alnylam reported full-year 2025 profitability and $2.987 billion in global net product revenues, driven by U.S. approval and growth of AMVUTTRA. The company also outlined 2026 pipeline goals and additional HELIOS-B analyses for vutrisiran.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07605169 |
Long-term Health and Economic Effects of an Individualized Lifestyle Intervention (LI-PAD-Extended) |
RECRUITING | NA |
| NCT07605052 |
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight |
NOT_YET_RECRUITING | PHASE1 |
| NCT07601555 |
Body Composition, Functional Capacity, and Respiratory Muscle Endurance in Obesity With Restrictive Ventilatory Pattern |
NOT_YET_RECRUITING | |
| NCT07601061 |
Simplifying Diet Tracking in a Digital Weight Loss Intervention |
NOT_YET_RECRUITING | NA |
| NCT07600866 |
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort |
NOT_YET_RECRUITING | |
| NCT07600411 |
Binge Eating, Depression and Anxiety Outcomes After Sleeve Gastrectomy Versus Gastric Bypass: A Cohort Study |
RECRUITING | NA |
| NCT07598981 |
PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry |
ENROLLING_BY_INVITATION | |
| NCT07597018 |
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07595822 |
Respiratory and Exercise Responses by Body Roundness Index in Obesity |
NOT_YET_RECRUITING | |
| NCT07595549 |
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE3 |
